Novartis AG ADR (NVS)vsAlpha Teknova Inc (TKNO)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
TKNO
Alpha Teknova Inc
$3.55
+9.91%
HEALTHCARE · Cap: $175.31M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 139530% more annual revenue ($56.58B vs $40.52M). NVS leads profitability with a 23.9% profit margin vs -42.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TKNO
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+34.3%
Fair Value
$3.24
Current Price
$3.55
$0.31 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -22.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TKNO
The strongest argument for TKNO centers on Debt/Equity, Price/Book.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : TKNO
The primary concerns for TKNO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while TKNO is a turnaround play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
TKNO is growing revenue faster at 7.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 23.9% margins. TKNO offers better value entry with a 34.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Alpha Teknova Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alpha Teknova Inc (TKNO) is a prominent player in the synthetic biology sector, providing essential biological reagents and supplements that support life sciences research and biomanufacturing. The company meets critical demands in areas such as vaccine development, cell and gene therapy, and diagnostic testing, driven by a dedication to quality and outstanding customer service. Leveraging its strong biotechnology foundation and an unwavering focus on innovation, Alpha Teknova is strategically positioned to seize growth opportunities in the rapidly evolving life sciences market, thereby enhancing value for its investors.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?